A team from Mount Sinai and Swift Biosciences used targeted sequencing to detect cancer mutations in uterine lavage fluid.
The partners plan to improve yields from small input samples and provide better sequencing libraries.
Both partners believe the agreement will help expand the scope of their services and give them additional markets for their products.
The companies will combine their technologies to create workflows for the next-generation sequencing of tumor cells obtained from FFPE samples.
The companies are combining their respective products to provide a solution that covers genetic testing from sample prep to clinical reports.
Swift will incorporate Horizon Discovery's NGS reference standards as a positive control in its oncology panel.
Researchers hope that newfound genetic information will help conservation efforts for the vaquita porpoise.
The jointly developed workflow uses Fluxion's IsoFlux system for circulating tumor cell enrichment along with Swift's Accel-Amplicon technology.
Agilent Technologies has optimized its SureSelect Target Enrichment solution for Life Technologies' Ion Proton.
NEW YORK (GenomeWeb News) – Swift Biosciences today said it has completed a Series B financing round that raised $7 million.
HHS Secretary Tom Price says the NIH budget contains unneeded expenses that can be trimmed, Stat News reports.
The chair of the House science committee says the journal Science is not objective, the Huffington Post reports.
In Nature this week: glioma GWAS uncovers new risk loci, and more.
Ivanka Trump and Secretary of Education Betsy DeVos call on girls to pursue STEM careers, the Associated Press reports.